Selecting the Right Antimicrobial Endpoints for Medical Device Product Testing

Medical device developers have more antimicrobial testing options than ever before, but selecting the right study remains a challenge. Throughout product development, teams must answer different questions about antimicrobial performance. One study may evaluate growth inhibition, while another assesses microbial killing or how an antimicrobial material performs on a device surface.

The challenge is that no single antimicrobial endpoint provides a complete picture of product performance. Relying on one testing method alone can leave important knowledge gaps, making it more difficult to optimize a product, compare formulations, or generate evidence that supports future regulatory activities.

Successful medical device product testing begins with understanding the questions a product evaluation needs to answer. By selecting antimicrobial endpoints that align with intended use, target microorganisms, and development objectives, manufacturers can generate relevant data that supports informed scientific decisions throughout development.

Why Multiple Antimicrobial Endpoints Matter in Medical Device Product Testing

Each antimicrobial test measures a different aspect of performance. Some evaluate microbial growth inhibition, others assess killing activity, and others examine how antimicrobial materials perform on device surfaces or under conditions that more closely reflect clinical use.

Because each endpoint provides different insights, antimicrobial testing strategies should be tailored to the product’s intended use rather than treated as a one-size-fits-all process.

For example, a developer screening antimicrobial formulations early in development may need different information than a team preparing evidence to support product performance or future antimicrobial claims. Selecting the right endpoint at the right stage helps ensure each study generates scientifically relevant data for the product’s specific application.

Build the Testing Strategy Around the Biological Question

Rather than asking which antimicrobial test is “best,” development teams should first ask:

What biological question are we trying to answer?

Once that objective is defined, teams can select the antimicrobial endpoint that provides the most relevant information. In many cases, combining complementary methods provides a broader understanding of antimicrobial performance throughout development.

MIC: Measuring Growth Inhibition

Minimum Inhibitory Concentration (MIC) studies determine the lowest concentration of an antimicrobial agent that prevents visible microbial growth.

In other words, MIC answers the question:

At what concentration does this active stop microorganisms from multiplying?

MIC provides a quantitative measure of antimicrobial potency, providing an apples to apples comparison to multiple active ingredients. This makes valuable during formulation development and early material screening before moving into more application-specific evaluations.

However, preventing growth is only one measure of antimicrobial performance.

MBC: Measuring Bactericidal Activity

Minimum Bactericidal Concentration (MBC) studies determine the lowest antimicrobial concentration required to kill microorganisms after exposure.

Instead of measuring growth inhibition, MBC evaluates where an antimicrobial demonstrates bactericidal activity.

Understanding the distinction between MIC vs. MBC is important because growth inhibition does not necessarily indicate microbial elimination. Together, these endpoints provide complementary insight into antimicrobial activity and help developers select formulations that align with product objectives.

Recognized Direct-Contact Methods Like AATCC 100

For many medical devices, antimicrobial performance depends on how treated materials interact directly with microorganisms on the device surface. In these situations, direct-contact testing can provide insights that solution-based assays cannot.

One commonly used approach is the AATCC 100 antimicrobial method, which evaluates microbial reduction following direct contact with antimicrobial-treated materials.

A key distinction is that AATCC 100 is recognized by the FDA as a method to support antimicrobial claims but is not standardized in the same way as an ISO or USP method. This provides flexibility in study design, allowing researchers to tailor testing to the intended application while generating reproducible antimicrobial data.

This flexibility can be particularly valuable when evaluating products with unique materials, antimicrobial technologies, or performance expectations.

When Biofilm Testing Provides Additional Insight

Many microorganisms encountered in healthcare settings do not remain free-floating. Instead, they attach to surfaces and develop into biofilms that can be significantly more difficult to eliminate.

Traditional planktonic testing remains an important component of antimicrobial evaluation, but it may not fully represent how microorganisms behave during actual device use.

When biofilm formation is relevant to a product’s intended application, antimicrobial testing and biofilm testing can provide additional insight into performance under more clinically relevant conditions. These application-specific studies help developers better understand how antimicrobial technologies perform in their intended uses.

Building a Multi-Endpoint Testing Strategy

Because each endpoint provides unique information, effective antimicrobial testing strategies combine multiple methods to evaluate performance from different perspectives.

A comprehensive strategy may include:

• MIC studies to prescreen active ingredient options
• MBC studies to evaluate bactericidal activity.
• The AATCC 100 antimicrobial method to assess antimicrobial performance on surfaces
• Biofilm antimicrobial testing when biofilm formation represents a clinically relevant consideration
• Additional application-specific studies designed to simulate real-world product use

By combining complementary endpoints, developers can move beyond isolated test results and build a more complete understanding of antimicrobial performance throughout product development.

The Value of Matching Endpoints in Medical Device Product Testing

A thoughtful antimicrobial testing strategy delivers benefits that extend beyond individual study results.

By selecting endpoints that align with product goals, development teams can generate reproducible scientific data, better understand how products perform under intended conditions, and make more informed design decisions.

This scientific foundation can also support future regulatory activities. When preparing a 510(k) submission for a medical device, selecting appropriate endpoints early helps build stronger evidence aligned with product performance objectives.

Ultimately, antimicrobial testing should be approached as a strategic process rather than a collection of disconnected studies. By matching endpoints to development goals, teams can reduce uncertainty, strengthen product decisions, and generate meaningful evidence that supports innovation from concept through commercialization.

iFyber works with medical device developers to design customized antimicrobial testing strategies that align with product goals, intended use, and regulatory objectives. From MIC and MBC studies to recognized methods like AATCC 100 and application-specific biofilm evaluations, iFyber provides scientific expertise and study design support to help ensure antimicrobial data is relevant, reproducible, and aligned with development needs.